

Jubilant Pharma Holdings Inc.
Balance Sheet as at 31 March 2016

	Note	As at 31 March 2016		As at 31 March 2015	
		USD	Rs. '000	USD	Rs. '000
EQUITY AND LIABILITIES					
Shareholders' funds					
Share capital	3	245,086,975	11,508,521	213,486,975	9,466,116
Reserves and surplus	4	(227,652)	4,713,410	(5,327,266)	3,543,867
		244,859,323	16,221,931	208,159,709	13,009,983
Current liabilities					
Short-term borrowings	5	34,100,000	2,259,125	37,750,000	2,359,375
Trade payables	6				
Total outstanding dues of creditors other than micro enterprises and small enterprises		701,959	46,505	46,460	2,904
Other current liabilities	7	2,501,887	165,750	1,372,089	85,756
Short-term provisions	8	150,861	9,995	-	-
		37,454,707	2,481,374	39,168,549	2,448,035
Total		282,314,030	18,703,306	247,328,258	15,458,018
ASSETS					
Non-current assets					
Fixed assets					
Tangible assets	9	206,882	13,706	-	-
Non-current investments	10	196,343,845	13,007,781	177,443,845	11,090,242
Long-term loans and advances	11	544,623	36,081	544,623	34,039
		197,095,350	13,057,568	177,988,468	11,124,281
Current assets					
Cash and bank balances	12	758,022	50,219	6,865,913	429,120
Short-term loans and advances	13	84,460,658	5,595,519	62,473,877	3,904,617
		85,218,680	5,645,738	69,339,790	4,333,737
Total		282,314,030	18,703,306	247,328,258	15,458,018

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date: 23 May, 2016

Jubilant Pharma Holdings Inc.

Statement of Profit and Loss for the year ended 31 March 2016

	Note	For the year ended 31 March 2016		For the year ended 31 March 2015	
		USD	Rs. '000	USD	Rs. '000
REVENUE					
Revenue from operations	14	7,234,000	473,552	-	-
Other operating income	15	3,463	227	16,351	999
Total revenue		7,237,463	473,779	16,351	999
EXPENSES					
Employee benefits expenses	16	3,975,002	261,650	335,119	20,894
Finance costs	17	1,010,027	65,972	1,163,682	71,252
Depreciation and amortization expense	9	10,667	719	-	-
Other expenses	18	950,296	62,657	210,104	12,984
Total expenses		5,945,992	390,998	1,708,905	105,130
Profit / (loss) before exceptional items and tax		1,291,471	82,781	(1,692,554)	(104,131)
Exceptional items	19	369,207	24,145	1,500,000	91,725
Profit / (loss) before tax		922,264	58,636	(3,192,554)	(195,856)
Tax expenses:					
- Current tax		38,316	2,536	2,000	122
- Deferred tax expense / (credit)		426,121	27,255	(591,776)	(37,405)
		464,437	29,791	(589,776)	(37,283)
Profit / (loss) for the year		457,827	28,845	(2,602,778)	(158,573)

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date: 23 May, 2016

Jubilant Pharma Holdings Inc.

Cash Flow Statement for the year ended 31 March 2016

	For the year ended 31 March 2016		For the year ended 31 March 2015	
	USD	Rs. '000	USD	Rs. '000
A. Cash flows from operating activities				
Profit / (loss) before tax	922,264	58,636	(3,192,554)	(195,856)
Adjustments:				
Depreciation and amortization expense	10,667	719	-	-
Finance costs	1,010,027	65,972	1,163,682	71,252
Provision for diminution in the value of investment	400,000	26,088	1,500,000	91,725
Interest income	(3,463)	(227)	(16,351)	(999)
	1,417,231	92,552	2,647,331	161,978
Operating profit / (loss) before working capital changes	2,339,495	151,188	(545,223)	(33,878)
Increase in trade and other receivables	(13,393,959)	(873,554)	(23,759,480)	(1,481,404)
Increase in investments	(27,900,000)	(1,819,638)	(2,440,100)	(152,140)
Increase in trade and other payable	5,003,772	326,346	12,439,393	775,596
Cash used in operations	(33,950,691)	(2,215,658)	(14,305,410)	(891,826)
Income tax paid (net of refund)	377,350	24,611	(135,403)	(8,280)
Interest received	3,463	227	16,351	999
Net cash used in operating activities	(33,569,878)	(2,190,820)	(14,424,462)	(899,107)
B. Cash flow from investing activities				
Acquisition/ purchase of fixed assets	(217,549)	(14,656)	-	-
Net cash used in investing activities	(217,549)	(14,656)	-	-
C. Cash flows from financing activities				
Proceeds from issue of equity share capital	31,600,000	2,042,405	-	-
Repayment of loan to fellow subsidiary - Jubilant Draximage Inc.	(3,650,000)	(238,053)	-	-
Loan from ultimate holding company - Jubilant Life Sciences Limited	-	-	13,000,000	794,950
Repayment of loan to ultimate holding company - Jubilant Life Sciences Limited	-	-	(21,700,000)	(1,326,955)
Loan from fellow subsidiary - Jubilant Cadista Pharmaceuticals Inc.	-	-	24,000,000	1,467,600
Finance cost paid	(270,464)	(17,640)	(1,006,444)	(61,544)
Net cash generated from financing activities	27,679,536	1,786,712	14,293,556	874,051
D. Foreign currency translation difference	-	39,863	-	34,997
Net decrease in cash and cash equivalents (A+B+C+D)	(6,107,891)	(378,902)	(130,906)	9,941
Add: cash and cash equivalents at the beginning of year	6,865,913	429,120	6,996,819	419,179
Cash and cash equivalents at the close of the year	758,022	50,219	6,865,913	429,120

Note:

Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date: 23 May, 2016

Jubilant Pharma Holdings Inc.

Notes to the financial statements for the year ended 31 March 2016

	As at 31 March 2016		As at 31 March 2015	
	USD	Rs. '000	USD	Rs. '000
3. SHARE CAPITAL				
Authorised				
Equity share capital 3,000 shares at zero par value (Previous year - 3000 shares at zero par value)	-	-	-	-
	-	-	-	-
Issued, Subscribed and Paid up				
Equity share capital 200 shares of class A and 1081 shares of class B common stock (Previous year 200 shares of class A and 911 shares of class B common stock)	245,086,975	11,508,521	213,486,975	9,466,116
	245,086,975	11,508,521	213,486,975	9,466,116

3.1) The Company has two classes of stock, Class A common stock and Class B common stock. The total number of shares of all classes of stock which the Company is authorized to issue is 3,000 shares of zero par value. Of the total authorized shares, 1,500 shares shall be authorized to be issued as Class A common stock, at zero par value and 1,500 shares shall be authorized to be issued as Class B common stock, at zero par value.

The voting powers for the shareholder shall be vested equally in the holders of Class A common stock and Class B common stock, with each share of stock entitled to one vote. No rights to class voting shall exist for either class of common stock.

The holder of Class A common stock shall have all rights and preferences with respect to dividend declared by the Company, except to the extent that the Board of Directors makes a special dividend declaration to the holders of Class B common stock.

Except for the foregoing dividend preference rights, Class A common stock and Class B common stock shall have equal rights with respect to (i) voting; (ii) liquidating distributions made to the shareholders; (iii) any distribution of the Company assets to its shareholders; and (iv) any other shareholder rights and privileges.

3.2) In the event of liquidation of the Company, the holders of equity shares shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of equity shares held by the stockholders.

3.3) The details of shares held by holding/ultimate holding company:

Name of the shareholders	As at 31 March 2016		As at 31 March 2015	
	No. of shares	USD	No. of shares	USD
Jubilant Pharma Limited, Singapore - the holding company Class B common stock at zero par value	1,081	207,886,975	911	176,286,975
Jubilant Generics Limited, India Class A common stock at zero par value	200	37,200,000	200.00	37,200,000

3.4) The details of shareholders holding more than 5% shares is set out below:

Name of the shareholders	As at 31 March 2016		As at 31 March 2015	
	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Limited, Singapore - the holding company	1,081	84.39%	911	82.00%
Jubilant Generics Limited, India	200	15.61%	200	18.00%

3.5) The reconciliation of the number of shares outstanding is set out below:

	As at 31 March 2016		As at 31 March 2015	
	No. of shares	Rs. '000	No. of shares	Rs. '000
At the commencement of the year	1,111	9,466,116	1,111	9,466,116
Additions during the year	170	2,042,405	-	-
At the end of the year	1,281	11,508,521	1,111	9,466,116

Jubilant Pharma Holdings Inc.
Notes to the financial statements for the year ended 31 March 2016

	As at 31 March 2016		As at 31 March 2015	
	USD	Rs. '000	USD	Rs. '000
4. RESERVES AND SURPLUS				
Foreign currency translation reserve				
At the commencement of the year	-	3,144,288	-	2,656,479
Additions during the year	-	837,961	-	487,809
At the end of the year	-	3,982,249	-	3,144,288
Capital reserve				
At the commencement of the year	64,546,179	3,800,292	21,025,000	1,138,972
Additions during the year (refer note 20 and 26)	4,641,787	302,737	43,521,179	2,661,320
At the end of the year	69,187,966	4,103,029	64,546,179	3,800,292
Deficit				
At the commencement of the year	(69,873,445)	(3,400,713)	(67,270,667)	(3,242,140)
Net Profit/(Loss) after tax transferred from statement of profit and loss	457,827	28,845	(2,602,778)	(158,573)
At the end of the year	(69,415,618)	(3,371,868)	(69,873,445)	(3,400,713)
	(227,652)	4,713,410	(5,327,266)	3,543,867
5. SHORT TERM BORROWINGS				
Loans from related parties (unsecured)(refer note 23)	34,100,000	2,259,125	37,750,000	2,359,375
	34,100,000	2,259,125	37,750,000	2,359,375
Above includes:				
i) Interest free loan from Jubilant Pharma Limited	10,100,000	669,125	10,100,000	631,250
iii) Loan from Jubilant DraxlImage Inc. carries interest @ 4% p.a.	-	-	3,650,000	228,125
iv) Loan from Jubilant Cadista Pharmaceuticals Inc. carries interest @ 4% p.a.	24,000,000	1,590,000	24,000,000	1,500,000
6. TRADE PAYABLES				
Total outstanding dues of creditors other than micro enterprises and small enterprises	701,959	46,505	46,460	2,904
	701,959	46,505	46,460	2,904
7. OTHER CURRENT LIABILITIES				
Interest accrued and due on borrowings (refer note 23)	1,084,004	71,815	344,441	21,528
Employee benefits	888,216	58,844	33,025	2,064
Due to related party (refer note 23)	529,667	35,090	994,623	62,164
	2,501,887	165,750	1,372,089	85,756
8. SHORT-TERM PROVISIONS				
Provision for employee benefits	150,861	9,995	-	-
	150,861	9,995	-	-

Jubilant Pharma Holdings Inc.
Notes to the financial statements for the year ended 31 March 2016

	As at 31 March 2016		As at 31 March 2015	
	USD	Rs. '000	USD	Rs. '000
10. NON-CURRENT INVESTMENTS				
(At Cost)				
Trade investments				
Investment in equity instruments (fully paid up equity shares)				
Jubilant Clinsys Inc. 39,797,557 shares (previous year 39,578,978 shares) of zero par value	71,754,324	4,753,724	71,354,324	4,459,645
HSL Holdings Inc. 1,853 shares (previous year 1,583 shares) @ USD 0.01 par value	129,685,000	8,591,632	110,785,000	6,924,064
Cadista Holdings Inc. * 117,797,190 shares (previous year 117,797,190 shares) @ USD 0.001 par value	66,658,745	4,416,142	66,658,745	4,166,172
Jubilant Pharma Trading Inc. 101 shares (previous year 101 shares) of zero par value	100	7	100	6
Less: Provision for diminution in the value of investment in Jubilant Clinsys Inc.	268,098,169 (71,754,324)	17,761,505 (4,753,724)	248,798,169 (71,354,324)	15,549,887 (4,459,645)
	196,343,845	13,007,781	177,443,845	11,090,242
*refer note 26				
11. LONG TERM LOANS AND ADVANCES				
Advance tax	544,623	36,081	544,623	34,039
	544,623	36,081	544,623	34,039
12. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	758,022	50,219	6,865,913	429,120
	758,022	50,219	6,865,913	429,120
13. SHORT-TERM LOANS AND ADVANCES				
Loans to related party (unsecured, considered good) (refer note 23)	71,616,000	4,744,560	61,816,000	3,863,500
Advance recoverable in cash and kind				
- From related parties (refer note 23)	12,832,456	850,150	657,877	41,117
- Others	12,202	809	-	-
	84,460,658	5,595,519	62,473,877	3,904,617

Jubilant Pharma Holdings Inc.
Notes to the financial statements for the year ended 31 March 2016

	For the year ended 31 March 2016		For the year ended 31 March 2015	
	USD	Rs. '000	USD	Rs. '000
14. REVENUE FROM OPERATIONS				
Sales of services	7,234,000	473,552	-	-
	7,234,000	473,552	-	-
15. OTHER OPERATING INCOME				
Interest income	3,463	227	16,351	999
	3,463	227	16,351	999
16. EMPLOYEE BENEFITS EXPENSES				
Salaries, wages and allowances	3,768,293	248,071	318,192	19,839
Contribution to social security schemes	116,516	7,661	12,528	781
Staff welfare expenses	90,193	5,918	4,399	274
	3,975,002	261,650	335,119	20,894
17. FINANCE COSTS				
Interest expense	1,010,027	65,972	1,163,682	71,252
	1,010,027	65,972	1,163,682	71,252
18. OTHER EXPENSES				
Rates and taxes	7,896	481	125	8
Auditors remuneration	17,100	1,120	6,318	388
Legal, professional and consultancy charges	245,878	16,376	142,015	8,745
Bank charges	2,756	181	2,642	164
Travelling and other incidental expenses	504,067	33,025	56,730	3,537
Communication expenses	23,984	1,577	442	28
Advertisement, publicity and sales promotion	28,465	1,896	550	34
Electricity expenses	13,101	872	-	-
Rent	38,808	2,571	-	-
Office Expenses	6,805	458	-	-
Staff recruitment & training	37,628	2,535	-	-
Subscription	11,671	767	-	-
Miscellaneous expenses	12,137	798	1,282	80
	950,296	62,657	210,104	12,984
19. EXCEPTIONAL ITEMS				
Foreign Exchange Gain	(30,793)	(1,943)	-	-
Diminution in value of investment (refer note 10)	400,000	26,088	1,500,000	91,725
	369,207	24,145	1,500,000	91,725